Ken Fisher Collegium Pharmaceutical, Inc Transaction History

Fisher Asset Management, LLC

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Dec 12, 2023	BUY	$21.06 - $24.0 $1.24 Million - $1.41 Million	58,742 New	58,742 $1.26 Million
Q2 2023 Aug 08, 2023	SELL	$21.06 - $24.0 $136,405 - $155,448	-6,477 Reduced 9.93%	58,742 $1.26 Million
Q1 2023 Dec 12, 2023	BUY	$23.0 - $29.88 $1.35 Million - $1.76 Million	58,742 New	58,742 $1.41 Million
Q2 2022 Aug 09, 2022	BUY	$14.22 - $20.88 $210,456 - $309,024	14,800 Added 29.35%	65,219 $1.16 Million
Q1 2022 May 05, 2022	BUY	$17.2 - $22.5 $186,207 - $243,585	10,826 Added 27.34%	50,419 $1.03 Million
Q4 2021 Feb 02, 2022	BUY	$17.5 - $21.35 $336,770 - $410,859	19,244 Added 94.57%	39,593 $740,000
Q3 2021 Oct 26, 2021	BUY	$17.75 - $25.39 $93,258 - $133,399	5,254 Added 34.81%	20,349 $402,000
Q4 2020 Jan 29, 2021	SELL	$17.83 - $22.29 $102,611 - $128,278	-5,755 Reduced 27.6%	15,095 $302,000
Q3 2020 Nov 10, 2020	SELL	$15.78 - $20.82 $106,609 - $140,659	-6,756 Reduced 24.47%	20,850 $434,000
Q2 2020 Aug 07, 2020	SELL	$15.49 - $23.51 $126,057 - $191,324	-8,138 Reduced 22.77%	27,606 $483,000
Q3 2018 Oct 24, 2018	SELL	$14.16 - $24.3 $184,816 - $317,163	-13,052 Reduced 26.75%	35,744 $527,000
Q2 2018 Jul 09, 2018	SELL	$21.79 - $28.29 $255,945 - $332,294	-11,746 Reduced 19.4%	48,796 $1.16 Million
Q1 2018 May 11, 2018	SELL	$18.15 - $29.21 $477,762 - $768,894	-26,323 Reduced 30.3%	60,542 $1.55 Million
Q1 2018 Apr 19, 2018	BUY	$18.15 - $29.21 $1.58 Million - $2.54 Million	86,865 New	86,865 $2.22 Million

254

36.9M

100K

21.1K

Ticker COLL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 34,126,200
Market Cap $1.12B
Description
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ...

Get notified when there are updates to the investment portfolio of Fisher Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Fisher Asset Management, LLC and Ken Fisher with notifications on news.